GlassScriptPhysician profile
Nadim Hawa
NPI 1932376290
$3,721.80
in general payments reported to CMS, 2019-2025
27 companies · $394 in 2025
The $394 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.84 · 2020: $80.30 · 2021: $278 · 2022: $2,169 · 2023: $319 · 2024: $398 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,874.53 | 2022-2025 | |
| Organon LLC | $319.22 | 2024-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $214.50 | 2021-2025 | Myosure Tissue Removal Device, Novasure, Omni Hysteroscope |
| Abbvie INC. | $158.25 | 2019-2022 | |
| Renovia INC | $134.79 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $128.61 | 2019-2023 | |
| Astellas Pharma US INC | $106.31 | 2023-2025 | Veozah |
| Coopersurgical, INC. | $103.98 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Sumitomo Pharma America, INC. | $77.50 | 2023-2024 | Myfembree |
| Ethicon US, LLC | $66.58 | 2021-2022 | |
| Aspira Women'S Health INC | $66.22 | 2022-2023 | Ova1 |
| Optumhealth Care Solutions, LLC | $60.48 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Daiichi Sankyo INC. | $59.54 | 2023-2024 | Injectafer |
| Dysis Medical, INC. | $59.07 | 2021-2023 | Dysis Ultra 2.0, Dysis V3 Digital Coploscope, Dysis View |
| Myovant Sciences INC. | $52.17 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $48.85 | 2022 | |
| Exact Sciences Corporation | $39.13 | 2023 | Cologuard Collection Kit |
| Shield Therapeutics INC | $26.42 | 2025 | |
| Therapeuticsmd, INC. | $18.52 | 2021 | |
| Acessa Health INC. | $17.63 | 2021 | |
| Evofem Biosciences, INC. | $16.47 | 2021 | |
| Sage Therapeutics, LLC | $15.24 | 2025 | Zurzuvae |
| Scynexis, INC. | $15.02 | 2022 | |
| Avion Pharmaceuticals | $14.57 | 2022 | |
| Mayne Pharma Commercial LLC | $14.40 | 2022 | |
| Pfizer INC. | $13.80 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadim Hawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.